Brought to you by 
Katama gets North American license to Sanochemia's tolperisone
08 May 2018
Executive Summary
Austrian pharmaco Sanochemia Pharmazeutika AG has licensed recently formed Katama Pharmaceuticals Inc. (initially focused on pain-related disorders) exclusive rights to develop and market its Phase II-ready tolperisone in North America.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Katama gets North American license to Sanochemia's tolperisone
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice